Biological agents in rheumatoid arthritis.
New potential therapies using molecular biology technology are under development. The initial trials in rheumatoid arthritis (RA) with interferon gamma were disappointing. Cytokine inhibitors such as interleukin-1 receptor antagonist are beginning clinical trials. Growth factors have been used to treat isolated complications associated with RA. Monoclonal antibodies to target active cell lines or receptors are also under study with preliminary results available from several studies. This technology offers a hope lf more selective interventions for many systemic rheumatic diseases.
Weinblatt
M E
ME
Department of Rheumatology and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D001688:Biological Products / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D001688:Biological Products; D006133:Growth Substances; D007371:Interferon-gamma